NRC HEALTH
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
NRC$25.86+1.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FINANCIAL INFORMATION Financial Statements Condensed Consolidated Balance Sheets
PART I**–** Financial Information**
ITEM 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts and par value)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,626 | $4,139 |
| Trade accounts receivable, less allowance for credit losses of $80 and $80, respectively | 15,341 | 11,108 |
| Prepaid expenses | 4,256 | 3,914 |
| Income taxes receivable | 2,920 | 528 |
| Other current assets | 567 | 520 |
| Total current assets | 26,710 | 20,209 |
| Property and equipment, net | 38,344 | 40,474 |
| Intangible assets, net | 2,041 | 2,227 |
| Goodwill | 66,152 | 66,152 |
| Deferred contract costs, net | 3,581 | 2,498 |
| Other noncurrent assets | 2,385 | 3,318 |
| Total assets | $139,213 | $134,878 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Current portion of notes payable, net of unamortized debt issuance costs | $4,767 | $4,014 |
| Accounts payable | 1,416 | 1,169 |
| Accrued wages and bonuses | 6,676 | 7,218 |
| Accrued expenses | 4,978 | 2,897 |
| Dividends payable | 3,406 | 3,625 |
| Deferred revenue | 20,277 | 16,201 |
| Income taxes payable | - | 550 |
| Other current liabilities | 325 | 946 |
| Total current liabilities | 41,845 | 36,620 |
| Notes payable, net of current portion and unamortized debt issuance costs | 98,133 | 75,021 |
| Deferred income taxes | 5,992 | 5,984 |
| Other long-term liabilities | 2,365 | 3,263 |
| Total liabilities | 148,335 | 120,888 |
| Shareholders’ equity: | ||
| Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued | - | - |
| Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,846,649 in 2026 and 31,966,504 in 2025, outstanding 21,221,538 in 2026 and 22,637,252 in 2025 | 32 | 32 |
| Additional paid-in capital | 192,864 | 183,880 |
| Accumulated deficit | (23,209) | (17,298) |
| Treasury stock, at cost; 10,625,111 and 9,329,252 Common shares in 2026 and 2025, respectively | (178,809) | (152,624) |
| Total shareholders’ equity | (9,122) | 13,990 |
| Total liabilities and shareholders’ equity | $139,213 | $134,878 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.